Glykind M Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. The synergistic effect of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone. Glykind M is typically prescribed when monotherapy with either agent is insufficient to achieve target glycemic levels. It is essential to administer the tablet with meals to minimize gastrointestinal side effects commonly associated with Metformin. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to ensure safety and efficacy. Contraindications include severe renal impairment, acute metabolic acidosis, and hypersensitivity to either component. Patients should be advised on lifestyle modifications, including diet and exercise, to optimize therapeutic outcomes. Glykind M Tablet offers a convenient and effective option for improving glycemic control in type 2 diabetes mellitus patients under appropriate medical supervision.